Comparison · NCT03806452-b4611a79
Hydroxycarbamide vs Placebo: Number of Patients Achieving at Least a 30% Decrease in ACR Baseline Value
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Hydroxycarbamide vs Placebo: Number of Patients Achieving at Least a 30% Decrease in ACR Baseline Value. Trial comparisons, record NCT03806452-b4611a79. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03806452-b4611a79
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.419 | 0.284 | 0.567 | wilson | |
| Risk in group 2 | 0.395 | 0.256 | 0.553 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0239 | -0.184 | 0.227 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.06 | 0.625 | 1.8 | log | |
| Odds ratio, group 1 over group 2 | 1.1 | 0.454 | 2.69 | log | |
| Number needed to treat, for one more participant with the outcome on Hydroxycarbamide than on Placebo | 41.9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Hydroxycarbamide | Hydroxycarbamide will be supplied as 100 mg or 1000 mg film-coated tablets. The posology will be based on the patient's body weight (bw). Hydroxycarbamide will be prescribed at a dose of 15 mg/kg bw/day and will be adminitered for 6 months.~Hydroxycarbamide will be administered for 12 months for patients qualified as responders willing to continue to participate in the trial.~Hydroxycarbamide: Hydroxycarbamide tablets of 100 and 1000 mg | 18 | 43 | OG000 |
| Group 2 | Placebo | Placebo will be supplied as 100 mg or 1000 mg film-coated tablets. The posology will be based on the patient's body weight (bw). Placebo will be prescribed at a dose of 15 mg/kg bw/day and will be adminitered for 6 months.~Hydroxycarbamide will be administered for 12 months for patients qualified as responders willing to continue to participate in the trial.~Placebo Oral Tablet: Placebo tablets of 100 and 1000 mg to mimic hydroxycarbamide tablets | 15 | 38 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Patients Achieving at Least a 30% Decrease in ACR Baseline Value
- Description
The primary endpoint of this study is the proportion of patients in the hydroxycarbamide and placebo groups achieving at least a 30% decrease in ACR baseline value at 6 months after treatment initiation. Patients who do not achieve at least a 30% decrease of the ACR baseline value at month 6 will be considered non-responders.
- Time frame
- 6 months
- Population
- 3 patients in the hydroxycarbamide arm and 2 patients in the placebo arm do not have any measure at 6 months and so were not part of this analysis
Source ClinicalTrials.gov
Trial
- Title
- SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial)
- NCT number
- NCT03806452
- Phases
- PHASE2
- Conditions
- Sickle Cell Disease
- Interventions
- Hydroxycarbamide, Placebo Oral Tablet
- Lead sponsor
- Theravia
- Results first posted
- 2025-05-14
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03806452?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03806452-b4611a79